Alkem Laboratories Limited has entered into an Amendment cum Supplemental Agreement dated 13th February, 2026 with its subsidiary Enzene Biosciences Limited and key investors. The agreement involves Eight Roads Ventures India Healthcare IV, L.P., F-Prime Capital Partners Life Sciences Fund VI LP, and ERVI Healthcare IV Holdings Limited for strategic fund infusion and governance amendments.

Agreement Structure and Fund Infusion

The Amendment cum Supplemental Agreement facilitates three key objectives: the allotment of securities by Enzene to F-Prime Capital and ERVI Healthcare on a preferential basis through private placement, adherence by ERVI Healthcare to the existing Shareholders' Agreement terms, and amendment of certain provisions of the original Shareholders' Agreement.

Securities Allocation Details

Under the preferential allotment arrangement, F-Prime Capital will subscribe to 1,30,451 Series B Compulsorily Convertible Preference Shares, while ERVI Healthcare will acquire 4,27,851 Series B CCPS along with 10 equity shares. Each security carries a face value of Rs. 10.00 and is priced at Rs. 468.60, including a premium of Rs. 458.60 per share.

Post-Allotment Shareholding Structure

Following the completion of the preferential allotment, the shareholding pattern in Enzene Biosciences will be restructured on a fully diluted basis:

Regulatory Compliance and Background

This disclosure follows Alkem's earlier intimations dated 23rd December, 2022 regarding the original Shareholders' Agreement and 11th August, 2023 concerning liability creation. The current amendment ensures ERVI Healthcare's adherence to the Shareholders' Agreement terms while facilitating the strategic investment in Enzene Biosciences.

Strategic Implications

The agreement maintains Alkem's controlling stake in its subsidiary Enzene Biosciences at 88.99% while bringing in additional capital and strategic partnerships. The transaction does not fall within related party transaction purview and has no impact on Alkem's management or control structure. The fund infusion strengthens Enzene's financial position for its biosciences operations and growth initiatives.

Alkem MedTech Private Limited, a wholly-owned subsidiary of Alkem Laboratories Limited, has announced a binding offer to acquire up to 55% stake in Swiss medical device company Occlutech Holding AG, marking the pharmaceutical company's strategic entry into the cardiovascular devices segment.

Acquisition Details

Through a binding offer executed on February 13, 2026, Alkem MedTech has proposed to acquire up to 55% of Occlutech Holding AG's equity share capital. The updated transaction parameters reflect the strategic importance of this acquisition:

Target Company Profile and Performance

Occlutech Holding AG, incorporated on December 12, 2000, is a Swiss medical device company specializing in minimally invasive cardiac implants for congenital heart defects, stroke prevention, and heart failure. The company holds the position as Europe's second-largest player in minimally invasive cardiac implants and third-largest globally.

Financial Performance Trajectory

Occlutech's financial performance demonstrates consistent growth with recent revenue expansion:

The company recorded EUR 49.40 million in revenue for calendar year 2025, representing a 15.7% compound annual growth rate over three years. Occlutech derives approximately 85% of its revenue from Europe and the United States.

Strategic Rationale and Market Position

The acquisition enables Alkem MedTech's entry into advanced cardiovascular devices, leveraging Occlutech's established global presence across over 80 countries. The target company operates manufacturing and R&D facilities in Germany and Turkey, with a global distribution hub in Sweden and clinical operations in the United States.

Executive Chairman B.N. Singh of Alkem Laboratories stated that the acquisition reinforces the company's long-term vision of becoming a global medical devices player. Kaustav Banerjee, CEO of Alkem MedTech, highlighted Occlutech's established capabilities and strong foundation for sustainable growth in high-barrier, high-value markets.

Regulatory Framework and Timeline

The transaction requires statutory approvals including foreign direct investment clearances in Italy and Sweden, with precautionary filing in France. The acquisition remains subject to definitive agreements, fulfillment of conditions precedent, and regulatory authorizations. Boston Consulting Group acted as advisor for this transaction, with completion expected by June 2026 following regulatory approvals.